BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33409752)

  • 1. Ovarian stimulation for fertility preservation in an oncology patient with etonogestrel implant in place.
    Rushing JS; Appiah L; Polotsky AJ; Murray S; Foust E; Hassell K; Roeca C
    J Assist Reprod Genet; 2021 Feb; 38(2):513-516. PubMed ID: 33409752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin.
    Carpinello O; Aserlind A; Chang F; Sagoskin A; Widra E
    F S Rep; 2020 Jun; 1(1):51-53. PubMed ID: 34223213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
    Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
    Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian response to stimulation for fertility preservation in women with hematologic cancer.
    Brun T; Dion L; Jaillard S; Bales D; Domin M; Lavoué V; Levêque J; Houot R; Duros S
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101925. PubMed ID: 33010467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients.
    Campos APC; Geber GP; Hurtado R; Sampaio M; Geber S
    JBRA Assist Reprod; 2018 Nov; 22(4):352-354. PubMed ID: 30264947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.
    Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C
    Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.
    Sonigo C; Comtet M; Duros S; Sifer C; Sermondade N; Grynberg M
    J Assist Reprod Genet; 2018 Jan; 35(1):91-97. PubMed ID: 28986734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bypassing physiological puberty, a novel procedure of oocyte cryopreservation at age 7: a case report and review of the literature.
    Azem F; Brener A; Malinger G; Reches A; Many A; Yogev Y; Lebenthal Y
    Fertil Steril; 2020 Aug; 114(2):374-378. PubMed ID: 32386868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oocyte cryopreservation for women with GATA2 deficiency.
    Zolton JR; Parikh TP; Hickstein DD; Holland SM; Hill MJ; DeCherney AH; Wolff EF
    J Assist Reprod Genet; 2018 Jul; 35(7):1201-1207. PubMed ID: 29532200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls.
    Decanter C; Robin G; Mailliez A; Sigala J; Morschhauser F; Ramdane N; Devos P; Dewailly D; Leroy-Martin B; Keller L
    Reprod Biomed Online; 2018 May; 36(5):543-551. PubMed ID: 29506861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
    Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
    Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
    Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
    Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of ovarian stimulation for oocyte cryopreservation in women with Turner syndrome.
    Talaulikar VS; Conway GS; Pimblett A; Davies MC
    Fertil Steril; 2019 Mar; 111(3):505-509. PubMed ID: 30598170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
    Marin L; Vitagliano A; Capobianco G; Dessole F; Ambrosini G; Andrisani A
    J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101815. PubMed ID: 32562778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.